Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 12 | 2022 | 66 | 2.820 |
Why?
|
| Analgesics, Opioid | 8 | 2022 | 104 | 2.360 |
Why?
|
| Ceftazidime | 3 | 2022 | 15 | 2.250 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2022 | 58 | 1.880 |
Why?
|
| Anti-Bacterial Agents | 8 | 2022 | 497 | 1.580 |
Why?
|
| Methadone | 4 | 2019 | 17 | 1.520 |
Why?
|
| Fentanyl | 5 | 2021 | 33 | 1.510 |
Why?
|
| Infant, Newborn | 13 | 2022 | 846 | 1.450 |
Why?
|
| Child | 25 | 2022 | 2159 | 1.300 |
Why?
|
| Retrospective Studies | 18 | 2023 | 2450 | 1.140 |
Why?
|
| Neonatal Abstinence Syndrome | 3 | 2019 | 10 | 1.140 |
Why?
|
| Anti-Infective Agents | 4 | 2017 | 77 | 1.130 |
Why?
|
| Infant | 13 | 2022 | 964 | 1.090 |
Why?
|
| Hypnotics and Sedatives | 6 | 2022 | 29 | 1.060 |
Why?
|
| Hyponatremia | 3 | 2021 | 16 | 1.020 |
Why?
|
| Humans | 48 | 2023 | 27067 | 1.000 |
Why?
|
| Gram-Negative Bacteria | 3 | 2022 | 58 | 1.000 |
Why?
|
| Ketamine | 2 | 2022 | 9 | 0.910 |
Why?
|
| Child, Preschool | 13 | 2021 | 1099 | 0.850 |
Why?
|
| Medication Therapy Management | 2 | 2019 | 18 | 0.810 |
Why?
|
| Cephalosporins | 1 | 2022 | 18 | 0.800 |
Why?
|
| Education, Pharmacy | 2 | 2021 | 108 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 589 | 0.750 |
Why?
|
| Meningitis | 1 | 2020 | 11 | 0.720 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 60 | 0.710 |
Why?
|
| Tobramycin | 2 | 2017 | 13 | 0.710 |
Why?
|
| Metronidazole | 2 | 2017 | 16 | 0.700 |
Why?
|
| Streptococcal Infections | 1 | 2020 | 34 | 0.700 |
Why?
|
| Pharmacy Residencies | 1 | 2020 | 6 | 0.690 |
Why?
|
| Bacteremia | 1 | 2020 | 80 | 0.680 |
Why?
|
| Pharmacists | 2 | 2022 | 69 | 0.680 |
Why?
|
| Obesity | 5 | 2023 | 654 | 0.670 |
Why?
|
| Students, Pharmacy | 2 | 2020 | 78 | 0.670 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 14 | 0.660 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2016 | 40 | 0.640 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 39 | 0.640 |
Why?
|
| Disease Management | 2 | 2017 | 85 | 0.640 |
Why?
|
| Opioid-Related Disorders | 4 | 2013 | 36 | 0.640 |
Why?
|
| Analgesics | 5 | 2016 | 35 | 0.630 |
Why?
|
| Infant, Premature | 2 | 2017 | 133 | 0.610 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2017 | 3 | 0.590 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2017 | 3 | 0.590 |
Why?
|
| Amiodarone | 1 | 2017 | 11 | 0.590 |
Why?
|
| Anesthetics, Intravenous | 1 | 2017 | 14 | 0.570 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2017 | 117 | 0.560 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2022 | 135 | 0.540 |
Why?
|
| Male | 19 | 2020 | 13003 | 0.520 |
Why?
|
| Aminoglycosides | 1 | 2014 | 10 | 0.480 |
Why?
|
| Hyperphosphatemia | 1 | 2014 | 4 | 0.470 |
Why?
|
| Pediatrics | 3 | 2022 | 87 | 0.470 |
Why?
|
| Female | 19 | 2020 | 14613 | 0.470 |
Why?
|
| Amphotericin B | 1 | 2014 | 17 | 0.470 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 4 | 0.470 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 218 | 0.460 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2019 | 10 | 0.460 |
Why?
|
| Body Fluids | 1 | 2014 | 18 | 0.460 |
Why?
|
| Narcotic Antagonists | 2 | 2011 | 31 | 0.460 |
Why?
|
| Antifungal Agents | 1 | 2014 | 58 | 0.450 |
Why?
|
| Language Development | 1 | 2013 | 4 | 0.450 |
Why?
|
| Alkalosis | 1 | 2013 | 2 | 0.440 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2013 | 6 | 0.440 |
Why?
|
| Acetazolamide | 1 | 2013 | 9 | 0.440 |
Why?
|
| Motor Skills | 1 | 2013 | 32 | 0.440 |
Why?
|
| Bumetanide | 1 | 2012 | 2 | 0.410 |
Why?
|
| Overweight | 2 | 2011 | 110 | 0.400 |
Why?
|
| Education, Pharmacy, Graduate | 3 | 2022 | 17 | 0.400 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 13 | 0.390 |
Why?
|
| Pharmaceutical Services | 2 | 2022 | 40 | 0.380 |
Why?
|
| Pharmacy | 2 | 2022 | 34 | 0.380 |
Why?
|
| Pruritus | 1 | 2011 | 8 | 0.380 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 99 | 0.360 |
Why?
|
| Cognition | 1 | 2013 | 298 | 0.360 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 73 | 0.350 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2009 | 9 | 0.340 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 26 | 0.330 |
Why?
|
| Medication Errors | 1 | 2009 | 26 | 0.330 |
Why?
|
| Adolescent | 7 | 2021 | 2986 | 0.330 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 113 | 0.310 |
Why?
|
| Otitis Media | 1 | 2007 | 35 | 0.290 |
Why?
|
| Clonidine | 3 | 2016 | 10 | 0.240 |
Why?
|
| Age Factors | 2 | 2019 | 721 | 0.240 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 39 | 0.240 |
Why?
|
| Vancomycin | 2 | 2017 | 56 | 0.240 |
Why?
|
| Acyclovir | 1 | 2023 | 8 | 0.220 |
Why?
|
| Educational Measurement | 2 | 2021 | 115 | 0.210 |
Why?
|
| Writing | 2 | 2020 | 14 | 0.210 |
Why?
|
| Cefotaxime | 1 | 2022 | 5 | 0.200 |
Why?
|
| Monobactams | 1 | 2022 | 6 | 0.200 |
Why?
|
| Curriculum | 3 | 2019 | 267 | 0.200 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 27 | 0.190 |
Why?
|
| Hydromorphone | 1 | 2021 | 7 | 0.190 |
Why?
|
| Chlorothiazide | 1 | 2021 | 3 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2019 | 859 | 0.180 |
Why?
|
| Fatty Acids, Essential | 1 | 2020 | 3 | 0.180 |
Why?
|
| Sodium | 1 | 2021 | 47 | 0.180 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 3 | 2016 | 10 | 0.180 |
Why?
|
| Ampicillin | 1 | 2020 | 13 | 0.180 |
Why?
|
| Streptococcus agalactiae | 1 | 2020 | 11 | 0.180 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2020 | 16 | 0.180 |
Why?
|
| Narration | 1 | 2020 | 20 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 73 | 0.170 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 104 | 0.170 |
Why?
|
| Research | 1 | 2020 | 88 | 0.170 |
Why?
|
| Internship and Residency | 1 | 2022 | 225 | 0.160 |
Why?
|
| Employment | 1 | 2019 | 45 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2022 | 330 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 21 | 0.160 |
Why?
|
| Career Choice | 1 | 2019 | 52 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 66 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 919 | 0.160 |
Why?
|
| Coronary Disease | 1 | 2019 | 118 | 0.150 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 63 | 0.150 |
Why?
|
| Injections, Intradermal | 1 | 2017 | 2 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 34 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2017 | 34 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 32 | 0.140 |
Why?
|
| Adult | 7 | 2023 | 7476 | 0.140 |
Why?
|
| Clostridium Infections | 1 | 2017 | 66 | 0.140 |
Why?
|
| Patient Admission | 1 | 2016 | 28 | 0.130 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 4 | 0.130 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 8 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 34 | 0.130 |
Why?
|
| Shock | 1 | 2016 | 17 | 0.130 |
Why?
|
| Norwood Procedures | 1 | 2016 | 12 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2016 | 67 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2016 | 67 | 0.120 |
Why?
|
| Amikacin | 1 | 2014 | 4 | 0.120 |
Why?
|
| Gentamicins | 1 | 2014 | 15 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 39 | 0.120 |
Why?
|
| Pregnancy | 1 | 2019 | 1148 | 0.120 |
Why?
|
| Phosphorus | 1 | 2014 | 51 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 171 | 0.110 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2013 | 23 | 0.110 |
Why?
|
| United States | 1 | 2019 | 2056 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 205 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2013 | 209 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2014 | 220 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 234 | 0.110 |
Why?
|
| Time Factors | 1 | 2017 | 1570 | 0.110 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2009 | 9 | 0.100 |
Why?
|
| Conscious Sedation | 1 | 2012 | 10 | 0.100 |
Why?
|
| Analgesia | 1 | 2012 | 12 | 0.100 |
Why?
|
| Nursing Assessment | 1 | 2012 | 27 | 0.100 |
Why?
|
| Critical Care | 1 | 2012 | 48 | 0.100 |
Why?
|
| Middle Aged | 3 | 2019 | 6882 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 404 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2012 | 28 | 0.100 |
Why?
|
| Pain Management | 1 | 2012 | 56 | 0.100 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2011 | 18 | 0.100 |
Why?
|
| Naloxone | 1 | 2011 | 18 | 0.100 |
Why?
|
| Naltrexone | 1 | 2011 | 19 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2012 | 97 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2016 | 605 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2012 | 396 | 0.090 |
Why?
|
| Risk Factors | 1 | 2014 | 2029 | 0.080 |
Why?
|
| Hospitalization | 1 | 2009 | 189 | 0.080 |
Why?
|
| Quality of Life | 1 | 2011 | 465 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2007 | 263 | 0.070 |
Why?
|
| Drug Tolerance | 2 | 2021 | 37 | 0.070 |
Why?
|
| Oklahoma | 2 | 2020 | 978 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 38 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 248 | 0.050 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2021 | 22 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2021 | 46 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2022 | 86 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2019 | 18 | 0.040 |
Why?
|
| Furosemide | 1 | 2019 | 7 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2019 | 72 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 43 | 0.040 |
Why?
|
| Occupations | 1 | 2018 | 9 | 0.040 |
Why?
|
| Feedback | 1 | 2018 | 32 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2019 | 221 | 0.040 |
Why?
|
| Aged | 2 | 2019 | 5212 | 0.040 |
Why?
|
| Education | 1 | 2018 | 33 | 0.040 |
Why?
|
| Scholarly Communication | 1 | 2018 | 3 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 252 | 0.040 |
Why?
|
| Accreditation | 1 | 2018 | 33 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 87 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 25 | 0.040 |
Why?
|
| Program Development | 1 | 2018 | 75 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2019 | 389 | 0.040 |
Why?
|
| Diarrhea | 1 | 2017 | 53 | 0.040 |
Why?
|
| Learning | 1 | 2018 | 94 | 0.040 |
Why?
|
| Inpatients | 1 | 2017 | 56 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 383 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 316 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 595 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 350 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 179 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 14 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 15 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 74 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 985 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 928 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 1936 | 0.030 |
Why?
|
| Opiate Substitution Treatment | 1 | 2013 | 5 | 0.030 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 7 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2012 | 163 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 30 | 0.020 |
Why?
|
| Anxiety | 1 | 2012 | 140 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 2278 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 749 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2624 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 299 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 398 | 0.020 |
Why?
|
| Dexmedetomidine | 1 | 2009 | 2 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 10073 | 0.010 |
Why?
|